期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识2016 被引量：77

原文传递
导出
摘要 肿瘤分子靶向治疗，是将肿瘤细胞表达而正常细胞较少表达或不表达的特定基因或基因的表达产物作为治疗靶点，以最大程度杀死肿瘤细胞而对正常细胞伤害较小的治疗模式。人表皮生长因子受体2（HER2）是乳腺癌患者重要的预后指标，也是抗HER2药物治疗的主要预测指标。
作者 江泽飞 邵志敏 徐兵河
机构地区 中国抗癌协会乳腺癌专业委员会
出处 《中华医学杂志》 CAS CSCD 北大核心 2016年第14期1091-1096,共6页 National Medical Journal of China
关键词 人表皮生长因子受体2 乳腺癌患者 临床诊疗 肿瘤细胞表达 分子靶向治疗 专家 阳性 正常细胞
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献30

  • 1江泽飞,邵志敏,徐兵河.人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识[J].中华肿瘤杂志,2010,32(2):158-160. 被引量：48
  • 2Wolff AC, Hammond MEH,Hicks DG, et al. Recommendationsfor human epidermal growth factor receptor 2 testing in breastcancer: American Society of Clinical Oncology/College ofAmerican Pathologists clinical practice guideline update. ArchPathol Lab Med, 2013,138(2) : 241-256. DOI: 10. 5858/arpa.2013-0953-SA.
  • 3乳腺癌HER2检测指南（2014版）[J].中华病理学杂志,2014,43(4):262-267. 被引量：297
  • 4Fabi A, Di Benedetto A, Metro G,et al. HER2 protein and genevariation between primary and metastaticbreast cancer :significance and impact on patient care. Clin Cancer Res, 2011,17(7) : 2055-2064. DOI: 10.1158/1078-0432. CCR-10-1920.
  • 5Robert N,Leylan-Jones B, Asmar L, et al. Randomized phase Idstudy of trastuzumab, paclitaxel, and carboplatin compared withtrastuzumab and paclitaxel in women with HER-2 -overexpressingmetastatic breast cancer[ J]. J Clin Oncol, 2006, 24(18) : 2786-2792.
  • 6Wardley AM, Pivot X,Morales-Vasquez F, et al. Randomizedphase II trial of first-line trastuzumab plus docetaxel andcapecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer [ J ]. J Clin Oncol,2010,28(6): 976-983. DOI: 10.1200/JC0.2008.21.6531.
  • 7Andersson M, Lidbrink E, Bjerre K, et al. Phase HI randomizedstudy comparing docetaxel plus trastuzumab with vinorelbine plustrastuzumab as first-line therapy of metastatic or locally advancedhuman epidermal growth factor receptor 2-positive breast cancer:The HERNATA study [J]. J Clin Oncol, 2011, 29 ( 3 ) : 264-271. DOI: 10.12OO/JCO. 2010. 30. 8213.
  • 8Schaller G, Fuchs I, Gonsch T,et al. Phase U Study ofCapecitabine Plus Trastuzumab in Human Epidermal GrowthFactor Receptor 2 -Overexpressing Metastatic Breast CancerPretreated With Anthracyclines or Taxanes [ J ]. J Clin Oncol,2007, 25(22) : 3246-3250.
  • 9Yardley DA, Burris HA, Hanson S, et al. Weekly gemcitabineand trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer[ J]. Clin Breast Cancer,2009 , 9(3) : 178-183. DOI: 10.3816/CBC.2009. n. 029.
  • 10Swain SM, Baselga J, Kim SB, et al. Pertuzumab, trastuzumab,and docetaxel in HER2-positive metastatic breast cancer [ J ] . NEngl J Med, 2015,372 ( 8 ) : 724-734. DOI: 10. 1056/NEJMoal413513.

二级参考文献30

  • 1张瑰红,施达仁,梁晓曼,侯景辉,康苏娅,朱卫东,李晓兵,邵云,陈丽荣,周燕.显色原位杂交和免疫组织化学检测乳腺癌HER2/neu基因状况和蛋白表达的对照性研究[J].中华病理学杂志,2006,35(10):580-583. 被引量：29
  • 2<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量：165
  • 3Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol, 2007, 25 : 118-145.
  • 4Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science, 1987, 235 : 177-182.
  • 5Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Eng J Med, 2001, 344:783- 792.
  • 6Marty M, Cognetti F, Maraninehi D, et al. Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol, 2005, 23: 4265 -4274.
  • 7Papaldo P, Fabi A, Ferretti G, et al. A phase Ⅱ study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. Ann Oncol, 2006, 17: 630-636.
  • 8Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase Ⅲ TANDEM study. J Clin Oncol, 2009, 27:5529-5537.
  • 9von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol, 2009, 27: 1999- 2006.
  • 10Cameron D, Casey M, Press M, et al. A phase Ⅲ randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat, 2008, 112:533-543.

共引文献341

同被引文献487

引证文献77

二级引证文献578

中华医学杂志
2016年 第14期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部